Clinical Trial Update: Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 1/2 study evaluating Fruquintinib in combination with Trastuzumab and XELOX as first-line therapy for HER2-positive…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Capecitabine (capecitabine)
• Fruquintinib (fruquintinib)
• OXALIPLATIN (Oxaliplatin)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Gastric Adenocarcinoma, Gastric (Stomach) Cancer | Phase 1, Phase 2 | Status: RECRUITING